At a glance
- Originator Aventis
- Class Antihyperlipidaemics
- Mechanism of Action HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
Most Recent Events
- 12 Jul 1999 No-Development-Reported for Hypercholesterolaemia in Germany (Unknown route)